Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Breast J. 2023 Feb 17;2023:9508632. doi: 10.1155/2023/9508632. eCollection 2023.
Myosin light chain plays a vital regulatory function in a large-scale cellular physiological procedure, however, the role of myosin light chain 5 (MYL5) in breast cancer has not been reported. In this study, we aimed to elucidate the effects of MYL5 on clinical prognosis and immune cell infiltration, and further explore the potential mechanism in breast cancer patients.
In this study, we first explored the expression pattern and prognostic value of MYL5 in breast cancer across multiple databases, including Oncomine, TCGA, GTEx, GEPIA2, PrognoScan, and Kaplan-Meier Plotter. The correlations of MYL5 expression with immune cell infiltration and associational gene markers in breast cancer were analyzed by using the TIMER, TIMER2.0, and TISIDB databases. The enrichment and prognosis analysis of MYL5-related genes were implemented by using LinkOmics datasets.
We found that there was a low expression of MYL5 in breast cancer than in corresponding normal tissue by analyzing the data from Oncomine and TCGA datasets. Furthermore, research showed the prognosis of the MYL5 high-expression group was better than the low-expression group in breast cancer patients. Furthermore, MYL5 expression is markedly related to the tumor-infiltrating immune cells (TIICs), including cancer-associated fibroblast, B cell, CD8 T cell, CD4 T cell, macrophage, neutrophil, and dendritic cell, and related to immune molecules as well as the associated gene markers of TIICs.
MYL5 can serve as a prognostic signature in breast cancer and is associated with immune infiltration. This study first offers a relatively comprehensive understanding of the oncogenic roles of MYL5 for breast cancer.
肌球蛋白轻链在大规模细胞生理过程中发挥着至关重要的调节作用，但肌球蛋白轻链 5（MYL5）在乳腺癌中的作用尚未见报道。在本研究中，我们旨在阐明 MYL5 对乳腺癌临床预后和免疫细胞浸润的影响，并进一步探讨乳腺癌患者中潜在的机制。
本研究首先通过 Oncomine、TCGA、GTEx、GEPIA2、PrognoScan 和 Kaplan-Meier Plotter 等多个数据库探讨了 MYL5 在乳腺癌中的表达模式和预后价值。通过 TIMER、TIMER2.0 和 TISIDB 数据库分析了 MYL5 表达与乳腺癌免疫细胞浸润和关联基因标志物的相关性。通过 LinkOmics 数据集进行了 MYL5 相关基因的富集和预后分析。
通过分析 Oncomine 和 TCGA 数据集的数据，我们发现 MYL5 在乳腺癌中的表达低于相应的正常组织。此外，研究表明，在乳腺癌患者中，MYL5 高表达组的预后优于低表达组。此外，MYL5 表达与肿瘤浸润免疫细胞（TIICs）显著相关，包括癌相关成纤维细胞、B 细胞、CD8 T 细胞、CD4 T 细胞、巨噬细胞、中性粒细胞和树突状细胞，以及与免疫分子和 TIICs 相关的基因标志物。
MYL5 可作为乳腺癌的预后标志物，并与免疫浸润相关。本研究首次提供了对 MYL5 致癌作用的相对全面的认识。
